Skip to content Skip to footer
Join our LinkedIn Group and be part of the conversation on AI in life sciences
Login
Login
Close

Meghan Oates-Zalesky 

Meghan Oates‑Zalesky is Chief Marketing Officer at CapeStart and MadeAi, with over 20 years of experience in healthcare technology and life sciences. Previously CMO at Apollo Intelligence, she helped grow the company from a small startup into a global enterprise. A PharmaVOICE Woman of Influence (2021), Meg’s thought leadership has appeared in leading industry publications. She holds degrees from Harvard and the London School of Economics and is a published novelist and avid equestrian.

98 articles published Follow:
csl-casestudy

From Social Media Conversations to Publication-Ready Evidence for CSL HEOR Team

Case StudyMarch 27, 2026124Views0Likes0Comments
How do you turn unstructured social media conversations into publication-ready evidence in just 4 weeks? In this case study, MadeAi partnered with the CSL HEOR team to identify and curate hereditary angioedema-related conversations from public online sources, with insights supporting a Value in Health Journal article. Using a structured social media listening approach, the team analyzed 3,069 records to uncover…

Read More

MadeAi | 2026 Prediction #3: Role-Based Tool Isolation: The Gold Standard for Secure Pharma AI

2026 Prediction #3: Role-Based Tool Isolation: The Gold Standard for Secure Pharma AI

BlogMarch 25, 2026134Views0Likes0Comments
The pharmaceutical industry is currently at a pivotal moment in the AI landscape. After years of cautious AI experimentation limited to isolated labs and pilot programs, something fundamentally different is unfolding in 2026. The central question has shifted from “Does AI work?” to “How do we deploy it safely and at scale?” especially in organizations…

Read More

AI-Powered GVD Automation_ Fast, Accurate, Compliant

AI-Powered GVD Automation: Fast, Accurate, Compliant

White PaperMarch 11, 2026122Views0Likes0Comments
Developing Global Value Dossiers (GVDs) is one of the most complex and time-consuming steps in the market access process. Medical Affairs, HEOR, and Regulatory teams must synthesize large volumes of clinical, economic, and real-world evidence while meeting the requirements of multiple HTA bodies across global markets. AI-powered GVD automation enables life sciences teams to accelerate…

Read More

AI Life Sciences

2026 Prediction #1: No More Sandboxes: AI Enters the Core of Life Sciences

BlogMarch 3, 2026263Views0Likes0Comments
For the last several years, artificial intelligence in life sciences has largely lived in innovation labs and pilot programs—valuable but often disconnected from the workflows that actually drive regulatory approvals, market access, and clinical decision-making. In 2026, that changes. Our first prediction from MadeAi & CapeStart’s 2026 outlook, developed with insights from Angeline Dhas, Head…

Read More